pr-inside.com
Back
Print

ArQule and Daiichi-Sankyo Enter Into Strategic R&D Partnership to Progress Novel Compounds to Target Cancer



2008-11-10 13:05:00 -

www.arqule.com - ArQule, Inc. William B. Boni, 781-994-0300 VP, Investor Relations/ Corp. Communications www.ArQule.com or Daiichi Sankyo (Tokyo) Toshiaki Sai, + 81-3-6225-1126 or Daiichi Sankyo, Inc. (USA) Richard Salem, 973-695-8330

Product development agreement focused on ARQ 197, c-Met inhibitor,
with discovery collaboration directed toward novel kinase inhibitors;

Total cash upfront to ArQule is $75 million;

ArQule's conference call scheduled today (November 10) at 9:00 AM
eastern time



Press release: www.pr-inside.com
Contact Information: email




Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.